Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: The National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI)

Zeeshan Butt*, Neehar D. Parikh, Jennifer L. Beaumont, Sarah K. Rosenbloom, Karen L. Syrjala, Amy P. Abernethy, Al B. Benson, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations


BACKGROUND: The 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire assesses health-related quality of life in patients with liver, bile duct, and pancreatic cancers. Although the FACT-Hep was initially derived from patient input, this study's researchers sought to verify adequate coverage of items by soliciting open-ended input from patients with advanced disease. METHODS: As part of a larger study in collaboration with the National Comprehensive Cancer Network (NCCN), 50 people (60% male, 80% caucasian, average age 60.4 years) with stage 3 or 4 hepatobiliary or pancreatic cancer were recruited. Participants generated and ranked up to 10 important symptoms and concerns that physicians should monitor when assessing the value of chemotherapy. Patients were also able to provide open-ended, qualitative information that was evaluated systematically. Ten expert physicians also provided input on priority symptoms. RESULTS: The resulting 18-item NCCN-FACT Hepatobiliary-Pancreatic Symptom Index (NFHSI-18) demonstrated high internal consistency (α =.89) and moderate to strong correlations with measures of physical well-being (ρ =.76), emotional well-being (ρ = 0.52), and functional well-being (ρ = 0.57). Scores on the NFHSI-18 were also highly correlated with the original hepatobiliary scale of the FACT-Hep (ρ =.82; all P <.001). Compared with patients with better performance status, patients with poor performance status had worse NFHSI-18 symptom scores, F(3,47) = 9.74; P =.0003. CONCLUSIONS: The NFHSI-18 assesses symptoms of importance to patients with hepatobiliary and pancreatic cancers and demonstrates promising measurement properties. The scale is a good candidate for brief symptom assessment in clinical trials.

Original languageEnglish (US)
Pages (from-to)5997-6004
Number of pages8
Issue number23
StatePublished - Dec 1 2012



  • advanced cancer
  • hepatobiliary cancer
  • pancreatic cancer
  • symptom assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this